NuVasive Acquires Biotronic NeuroNetwork for $98 Million

| Printer friendly version

NuVasive, Inc., has announced it has agreed to acquire Biotronic NeuroNetwork for $98 million cash. According to the press release, the acquisition more than doubles NuVasive’s footprint in the neurophysiology business across the U.S., and extends NuVasive’s efforts to expand its spine service line partnerships in the industry.



Biotronic provides intraoperative neurophysiological monitoring services to surgeons and healthcare facilities nationwide.  According to the press release, Biotronic supports more than 45,000 surgeries annually in over 650 hospitals nationwide by providing certified specialists to monitor patients’ nervous systems during surgery. Biotronic reported over $50 million in revenue in 2015. NuVasive also provides intraoperative neurophysiological monitoring services to surgeons and healthcare facilities through its subsidiary, Impulse Monitoring, Inc. With the acquisition, NuVasive plans to combine the service offerings of Biotronic with Impulse Monitoring to create NuVasive Clinical Services.  NuVasive Clinical Services is expected to support more than 75,000 cases annually in the United States, and will be headed by Doug Karczewski, who has led NuVasive’s Eastern U.S. Commercial organization for the last three years.

This news follows NuVasive’s recent acquisition of Ellipse Technologies, Inc., in January of this year for $380 million cash, with a possible $30 million milestone payment in 2017. Ellipse developed and marketed a novel platform of adjustable spinal implant systems based on its MAGnetic External Control, or MAGEC®, technology. The MAGEC® technology allows physicians to customize therapy for patients in a noninvasive manner, using a remote controller to lengthen or shorten an implanted spinal rod.Ellipse

According to its website, NuVasive is the third largest medical device company in the global spine industry and features more than 90 products spanning lumbar, thoracic, and cervical applications, neuromonitoring services, and a biologics portfolio.

Mitch Hadley
Mitchell Hadley is an associate in our San Diego office. His practice involves all aspects of patent prosecution. Prior to joining the firm, Mr. Hadley attended law school at the Brigham Young University, J. Reuben Clark Law School where he graduated magna cum laude and was elected to the Order of the Coif. During law school he served as Lead Note and Comment Editor of the BYU law Review. In 2010, he graduated from Brigham Young University with a B.S. in Mechanical Engineering. Mr. Hadley joined the firm in 2014 after working as summer associate in the firm's San Diego office during the summer of 2013.
Click here to read full bio
View all posts published by Mitch Hadley »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.